Neoantigen Cancer Vaccine Market - Global Outlook and Forecast 2022-2028

January 2022 | 69 pages | ID: N8DC9A46973EEN
Market Monitor Global

Abstracts

It is through the use of tumor cell-associated antigens to awaken the body's immune system against cancer.

This report contains market size and forecasts of Neoantigen Cancer Vaccine in Global, including the following market information:

Global Neoantigen Cancer Vaccine Market Revenue, 2017-2022, 2023-2028, ($ millions)

Global top five companies in 2021 (%)

The global Neoantigen Cancer Vaccine market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

Personalized Vaccine Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Neoantigen Cancer Vaccine include Roche, Medimmune, Merck, Advaxis, Agenus, Genocea, Gritstone Oncology, Neon Therapeutics and Nouscom, etc. In 2021, the global top five players have a share approximately % in terms of revenue.

MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Neoantigen Cancer Vaccine companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Neoantigen Cancer Vaccine Market, by Type, 2017-2022, 2023-2028 ($ millions)

Global Neoantigen Cancer Vaccine Market Segment Percentages, by Type, 2021 (%)

• Personalized Vaccine
• Off-the-shelf Neovaccines

Global Neoantigen Cancer Vaccine Market, by Application, 2017-2022, 2023-2028 ($ millions)

Global Neoantigen Cancer Vaccine Market Segment Percentages, by Application, 2021 (%)

• Hospital
• Clinic
• Others

Global Neoantigen Cancer Vaccine Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)

Global Neoantigen Cancer Vaccine Market Segment Percentages, By Region and Country, 2021 (%)

• North America
• US
• Canada
• Mexico
• Europe
• Germany
• France
• U.K.
• Italy
• Russia
• Nordic Countries
• Benelux
• Rest of Europe
• Asia
• China
• Japan
• South Korea
• Southeast Asia
• India
• Rest of Asia
• South America
• Brazil
• Argentina
• Rest of South America
• Middle East & Africa
• Turkey
• Israel
• Saudi Arabia
• UAE
• Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Neoantigen Cancer Vaccine revenues in global market, 2017-2022 (estimated), ($ millions)

Key companies Neoantigen Cancer Vaccine revenues share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

• Roche
• Medimmune
• Merck
• Advaxis
• Agenus
• Genocea
• Gritstone Oncology
• Neon Therapeutics
• Nouscom
• OSE Immunotherapeutics
• Medigene
• Vaccibody
• Brightpath Biotherapeutics
• Geneos Therapeutics

Contents

1 INTRODUCTION TO RESEARCH & ANALYSIS REPORTS

1.1 Neoantigen Cancer Vaccine Market Definition
1.2 Market Segments
  1.2.1 Market by Type
  1.2.2 Market by Application
1.3 Global Neoantigen Cancer Vaccine Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
  1.5.1 Research Methodology
  1.5.2 Research Process
  1.5.3 Base Year
  1.5.4 Report Assumptions & Caveats

2 GLOBAL NEOANTIGEN CANCER VACCINE OVERALL MARKET SIZE

2.1 Global Neoantigen Cancer Vaccine Market Size: 2021 VS 2028
2.2 Global Neoantigen Cancer Vaccine Market Size, Prospects & Forecasts: 2017-2028
2.3 Key Market Trends, Opportunity, Drivers and Restraints
  2.3.1 Market Opportunities & Trends
  2.3.2 Market Drivers
  2.3.3 Market Restraints

3 COMPANY LANDSCAPE

3.1 Top Neoantigen Cancer Vaccine Players in Global Market
3.2 Top Global Neoantigen Cancer Vaccine Companies Ranked by Revenue
3.3 Global Neoantigen Cancer Vaccine Revenue by Companies
3.4 Top 3 and Top 5 Neoantigen Cancer Vaccine Companies in Global Market, by Revenue in 2021
3.5 Global Companies Neoantigen Cancer Vaccine Product Type
3.6 Tier 1, Tier 2 and Tier 3 Neoantigen Cancer Vaccine Players in Global Market
  3.6.1 List of Global Tier 1 Neoantigen Cancer Vaccine Companies
  3.6.2 List of Global Tier 2 and Tier 3 Neoantigen Cancer Vaccine Companies

4 MARKET SIGHTS BY PRODUCT

4.1 Overview
  4.1.1 by Type - Global Neoantigen Cancer Vaccine Market Size Markets, 2021 & 2028
  4.1.2 Personalized Vaccine
  4.1.3 Off-the-shelf Neovaccines
4.2 By Type - Global Neoantigen Cancer Vaccine Revenue & Forecasts
  4.2.1 By Type - Global Neoantigen Cancer Vaccine Revenue, 2017-2022
  4.2.2 By Type - Global Neoantigen Cancer Vaccine Revenue, 2023-2028
  4.2.3 By Type - Global Neoantigen Cancer Vaccine Revenue Market Share, 2017-2028

5 SIGHTS BY APPLICATION

5.1 Overview
  5.1.1 By Application - Global Neoantigen Cancer Vaccine Market Size, 2021 & 2028
  5.1.2 Hospital
  5.1.3 Clinic
  5.1.4 Others
5.2 By Application - Global Neoantigen Cancer Vaccine Revenue & Forecasts
  5.2.1 By Application - Global Neoantigen Cancer Vaccine Revenue, 2017-2022
  5.2.2 By Application - Global Neoantigen Cancer Vaccine Revenue, 2023-2028
  5.2.3 By Application - Global Neoantigen Cancer Vaccine Revenue Market Share, 2017-2028

6 SIGHTS BY REGION

6.1 By Region - Global Neoantigen Cancer Vaccine Market Size, 2021 & 2028
6.2 By Region - Global Neoantigen Cancer Vaccine Revenue & Forecasts
  6.2.1 By Region - Global Neoantigen Cancer Vaccine Revenue, 2017-2022
  6.2.2 By Region - Global Neoantigen Cancer Vaccine Revenue, 2023-2028
  6.2.3 By Region - Global Neoantigen Cancer Vaccine Revenue Market Share, 2017-2028
6.3 North America
  6.3.1 By Country - North America Neoantigen Cancer Vaccine Revenue, 2017-2028
  6.3.2 US Neoantigen Cancer Vaccine Market Size, 2017-2028
  6.3.3 Canada Neoantigen Cancer Vaccine Market Size, 2017-2028
  6.3.4 Mexico Neoantigen Cancer Vaccine Market Size, 2017-2028
6.4 Europe
  6.4.1 By Country - Europe Neoantigen Cancer Vaccine Revenue, 2017-2028
  6.4.2 Germany Neoantigen Cancer Vaccine Market Size, 2017-2028
  6.4.3 France Neoantigen Cancer Vaccine Market Size, 2017-2028
  6.4.4 U.K. Neoantigen Cancer Vaccine Market Size, 2017-2028
  6.4.5 Italy Neoantigen Cancer Vaccine Market Size, 2017-2028
  6.4.6 Russia Neoantigen Cancer Vaccine Market Size, 2017-2028
  6.4.7 Nordic Countries Neoantigen Cancer Vaccine Market Size, 2017-2028
  6.4.8 Benelux Neoantigen Cancer Vaccine Market Size, 2017-2028
6.5 Asia
  6.5.1 By Region - Asia Neoantigen Cancer Vaccine Revenue, 2017-2028
  6.5.2 China Neoantigen Cancer Vaccine Market Size, 2017-2028
  6.5.3 Japan Neoantigen Cancer Vaccine Market Size, 2017-2028
  6.5.4 South Korea Neoantigen Cancer Vaccine Market Size, 2017-2028
  6.5.5 Southeast Asia Neoantigen Cancer Vaccine Market Size, 2017-2028
  6.5.6 India Neoantigen Cancer Vaccine Market Size, 2017-2028
6.6 South America
  6.6.1 By Country - South America Neoantigen Cancer Vaccine Revenue, 2017-2028
  6.6.2 Brazil Neoantigen Cancer Vaccine Market Size, 2017-2028
  6.6.3 Argentina Neoantigen Cancer Vaccine Market Size, 2017-2028
6.7 Middle East & Africa
  6.7.1 By Country - Middle East & Africa Neoantigen Cancer Vaccine Revenue, 2017-2028
  6.7.2 Turkey Neoantigen Cancer Vaccine Market Size, 2017-2028
  6.7.3 Israel Neoantigen Cancer Vaccine Market Size, 2017-2028
  6.7.4 Saudi Arabia Neoantigen Cancer Vaccine Market Size, 2017-2028
  6.7.5 UAE Neoantigen Cancer Vaccine Market Size, 2017-2028

7 PLAYERS PROFILES

7.1 Roche
  7.1.1 Roche Corporate Summary
  7.1.2 Roche Business Overview
  7.1.3 Roche Neoantigen Cancer Vaccine Major Product Offerings
  7.1.4 Roche Neoantigen Cancer Vaccine Revenue in Global Market (2017-2022)
  7.1.5 Roche Key News
7.2 Medimmune
  7.2.1 Medimmune Corporate Summary
  7.2.2 Medimmune Business Overview
  7.2.3 Medimmune Neoantigen Cancer Vaccine Major Product Offerings
  7.2.4 Medimmune Neoantigen Cancer Vaccine Revenue in Global Market (2017-2022)
  7.2.5 Medimmune Key News
7.3 Merck
  7.3.1 Merck Corporate Summary
  7.3.2 Merck Business Overview
  7.3.3 Merck Neoantigen Cancer Vaccine Major Product Offerings
  7.3.4 Merck Neoantigen Cancer Vaccine Revenue in Global Market (2017-2022)
  7.3.5 Merck Key News
7.4 Advaxis
  7.4.1 Advaxis Corporate Summary
  7.4.2 Advaxis Business Overview
  7.4.3 Advaxis Neoantigen Cancer Vaccine Major Product Offerings
  7.4.4 Advaxis Neoantigen Cancer Vaccine Revenue in Global Market (2017-2022)
  7.4.5 Advaxis Key News
7.5 Agenus
  7.5.1 Agenus Corporate Summary
  7.5.2 Agenus Business Overview
  7.5.3 Agenus Neoantigen Cancer Vaccine Major Product Offerings
  7.5.4 Agenus Neoantigen Cancer Vaccine Revenue in Global Market (2017-2022)
  7.5.5 Agenus Key News
7.6 Genocea
  7.6.1 Genocea Corporate Summary
  7.6.2 Genocea Business Overview
  7.6.3 Genocea Neoantigen Cancer Vaccine Major Product Offerings
  7.6.4 Genocea Neoantigen Cancer Vaccine Revenue in Global Market (2017-2022)
  7.6.5 Genocea Key News
7.7 Gritstone Oncology
  7.7.1 Gritstone Oncology Corporate Summary
  7.7.2 Gritstone Oncology Business Overview
  7.7.3 Gritstone Oncology Neoantigen Cancer Vaccine Major Product Offerings
  7.7.4 Gritstone Oncology Neoantigen Cancer Vaccine Revenue in Global Market (2017-2022)
  7.7.5 Gritstone Oncology Key News
7.8 Neon Therapeutics
  7.8.1 Neon Therapeutics Corporate Summary
  7.8.2 Neon Therapeutics Business Overview
  7.8.3 Neon Therapeutics Neoantigen Cancer Vaccine Major Product Offerings
  7.8.4 Neon Therapeutics Neoantigen Cancer Vaccine Revenue in Global Market (2017-2022)
  7.8.5 Neon Therapeutics Key News
7.9 Nouscom
  7.9.1 Nouscom Corporate Summary
  7.9.2 Nouscom Business Overview
  7.9.3 Nouscom Neoantigen Cancer Vaccine Major Product Offerings
  7.9.4 Nouscom Neoantigen Cancer Vaccine Revenue in Global Market (2017-2022)
  7.9.5 Nouscom Key News
7.10 OSE Immunotherapeutics
  7.10.1 OSE Immunotherapeutics Corporate Summary
  7.10.2 OSE Immunotherapeutics Business Overview
  7.10.3 OSE Immunotherapeutics Neoantigen Cancer Vaccine Major Product Offerings
  7.10.4 OSE Immunotherapeutics Neoantigen Cancer Vaccine Revenue in Global Market (2017-2022)
  7.10.5 OSE Immunotherapeutics Key News
7.11 Medigene
  7.11.1 Medigene Corporate Summary
  7.11.2 Medigene Business Overview
  7.11.3 Medigene Neoantigen Cancer Vaccine Major Product Offerings
  7.11.4 Medigene Neoantigen Cancer Vaccine Revenue in Global Market (2017-2022)
  7.11.5 Medigene Key News
7.12 Vaccibody
  7.12.1 Vaccibody Corporate Summary
  7.12.2 Vaccibody Business Overview
  7.12.3 Vaccibody Neoantigen Cancer Vaccine Major Product Offerings
  7.12.4 Vaccibody Neoantigen Cancer Vaccine Revenue in Global Market (2017-2022)
  7.12.5 Vaccibody Key News
7.13 Brightpath Biotherapeutics
  7.13.1 Brightpath Biotherapeutics Corporate Summary
  7.13.2 Brightpath Biotherapeutics Business Overview
  7.13.3 Brightpath Biotherapeutics Neoantigen Cancer Vaccine Major Product Offerings
  7.13.4 Brightpath Biotherapeutics Neoantigen Cancer Vaccine Revenue in Global Market (2017-2022)
  7.13.5 Brightpath Biotherapeutics Key News
7.14 Geneos Therapeutics
  7.14.1 Geneos Therapeutics Corporate Summary
  7.14.2 Geneos Therapeutics Business Overview
  7.14.3 Geneos Therapeutics Neoantigen Cancer Vaccine Major Product Offerings
  7.14.4 Geneos Therapeutics Neoantigen Cancer Vaccine Revenue in Global Market (2017-2022)
  7.14.5 Geneos Therapeutics Key News

8 CONCLUSION

9 APPENDIX

9.1 Note
9.2 Examples of Clients
9.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. Neoantigen Cancer Vaccine Market Opportunities & Trends in Global Market
Table 2. Neoantigen Cancer Vaccine Market Drivers in Global Market
Table 3. Neoantigen Cancer Vaccine Market Restraints in Global Market
Table 4. Key Players of Neoantigen Cancer Vaccine in Global Market
Table 5. Top Neoantigen Cancer Vaccine Players in Global Market, Ranking by Revenue (2021)
Table 6. Global Neoantigen Cancer Vaccine Revenue by Companies, (US$, Mn), 2017-2022
Table 7. Global Neoantigen Cancer Vaccine Revenue Share by Companies, 2017-2022
Table 8. Global Companies Neoantigen Cancer Vaccine Product Type
Table 9. List of Global Tier 1 Neoantigen Cancer Vaccine Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Neoantigen Cancer Vaccine Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 11. By Type – Global Neoantigen Cancer Vaccine Revenue, (US$, Mn), 2021 & 2028
Table 12. By Type - Neoantigen Cancer Vaccine Revenue in Global (US$, Mn), 2017-2022
Table 13. By Type - Neoantigen Cancer Vaccine Revenue in Global (US$, Mn), 2023-2028
Table 14. By Application – Global Neoantigen Cancer Vaccine Revenue, (US$, Mn), 2021 & 2028
Table 15. By Application - Neoantigen Cancer Vaccine Revenue in Global (US$, Mn), 2017-2022
Table 16. By Application - Neoantigen Cancer Vaccine Revenue in Global (US$, Mn), 2023-2028
Table 17. By Region – Global Neoantigen Cancer Vaccine Revenue, (US$, Mn), 2021 & 2028
Table 18. By Region - Global Neoantigen Cancer Vaccine Revenue (US$, Mn), 2017-2022
Table 19. By Region - Global Neoantigen Cancer Vaccine Revenue (US$, Mn), 2023-2028
Table 20. By Country - North America Neoantigen Cancer Vaccine Revenue, (US$, Mn), 2017-2022
Table 21. By Country - North America Neoantigen Cancer Vaccine Revenue, (US$, Mn), 2023-2028
Table 22. By Country - Europe Neoantigen Cancer Vaccine Revenue, (US$, Mn), 2017-2022
Table 23. By Country - Europe Neoantigen Cancer Vaccine Revenue, (US$, Mn), 2023-2028
Table 24. By Region - Asia Neoantigen Cancer Vaccine Revenue, (US$, Mn), 2017-2022
Table 25. By Region - Asia Neoantigen Cancer Vaccine Revenue, (US$, Mn), 2023-2028
Table 26. By Country - South America Neoantigen Cancer Vaccine Revenue, (US$, Mn), 2017-2022
Table 27. By Country - South America Neoantigen Cancer Vaccine Revenue, (US$, Mn), 2023-2028
Table 28. By Country - Middle East & Africa Neoantigen Cancer Vaccine Revenue, (US$, Mn), 2017-2022
Table 29. By Country - Middle East & Africa Neoantigen Cancer Vaccine Revenue, (US$, Mn), 2023-2028
Table 30. Roche Corporate Summary
Table 31. Roche Neoantigen Cancer Vaccine Product Offerings
Table 32. Roche Neoantigen Cancer Vaccine Revenue (US$, Mn), (2017-2022)
Table 33. Medimmune Corporate Summary
Table 34. Medimmune Neoantigen Cancer Vaccine Product Offerings
Table 35. Medimmune Neoantigen Cancer Vaccine Revenue (US$, Mn), (2017-2022)
Table 36. Merck Corporate Summary
Table 37. Merck Neoantigen Cancer Vaccine Product Offerings
Table 38. Merck Neoantigen Cancer Vaccine Revenue (US$, Mn), (2017-2022)
Table 39. Advaxis Corporate Summary
Table 40. Advaxis Neoantigen Cancer Vaccine Product Offerings
Table 41. Advaxis Neoantigen Cancer Vaccine Revenue (US$, Mn), (2017-2022)
Table 42. Agenus Corporate Summary
Table 43. Agenus Neoantigen Cancer Vaccine Product Offerings
Table 44. Agenus Neoantigen Cancer Vaccine Revenue (US$, Mn), (2017-2022)
Table 45. Genocea Corporate Summary
Table 46. Genocea Neoantigen Cancer Vaccine Product Offerings
Table 47. Genocea Neoantigen Cancer Vaccine Revenue (US$, Mn), (2017-2022)
Table 48. Gritstone Oncology Corporate Summary
Table 49. Gritstone Oncology Neoantigen Cancer Vaccine Product Offerings
Table 50. Gritstone Oncology Neoantigen Cancer Vaccine Revenue (US$, Mn), (2017-2022)
Table 51. Neon Therapeutics Corporate Summary
Table 52. Neon Therapeutics Neoantigen Cancer Vaccine Product Offerings
Table 53. Neon Therapeutics Neoantigen Cancer Vaccine Revenue (US$, Mn), (2017-2022)
Table 54. Nouscom Corporate Summary
Table 55. Nouscom Neoantigen Cancer Vaccine Product Offerings
Table 56. Nouscom Neoantigen Cancer Vaccine Revenue (US$, Mn), (2017-2022)
Table 57. OSE Immunotherapeutics Corporate Summary
Table 58. OSE Immunotherapeutics Neoantigen Cancer Vaccine Product Offerings
Table 59. OSE Immunotherapeutics Neoantigen Cancer Vaccine Revenue (US$, Mn), (2017-2022)
Table 60. Medigene Corporate Summary
Table 61. Medigene Neoantigen Cancer Vaccine Product Offerings
Table 62. Medigene Neoantigen Cancer Vaccine Revenue (US$, Mn), (2017-2022)
Table 63. Vaccibody Corporate Summary
Table 64. Vaccibody Neoantigen Cancer Vaccine Product Offerings
Table 65. Vaccibody Neoantigen Cancer Vaccine Revenue (US$, Mn), (2017-2022)
Table 66. Brightpath Biotherapeutics Corporate Summary
Table 67. Brightpath Biotherapeutics Neoantigen Cancer Vaccine Product Offerings
Table 68. Brightpath Biotherapeutics Neoantigen Cancer Vaccine Revenue (US$, Mn), (2017-2022)
Table 69. Geneos Therapeutics Corporate Summary
Table 70. Geneos Therapeutics Neoantigen Cancer Vaccine Product Offerings
Table 71. Geneos Therapeutics Neoantigen Cancer Vaccine Revenue (US$, Mn), (2017-2022)

List Of Figures

LIST OF FIGURES

Figure 1. Neoantigen Cancer Vaccine Segment by Type in 2021
Figure 2. Neoantigen Cancer Vaccine Segment by Application in 2021
Figure 3. Global Neoantigen Cancer Vaccine Market Overview: 2021
Figure 4. Key Caveats
Figure 5. Global Neoantigen Cancer Vaccine Market Size: 2021 VS 2028 (US$, Mn)
Figure 6. Global Neoantigen Cancer Vaccine Revenue, 2017-2028 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Neoantigen Cancer Vaccine Revenue in 2021
Figure 8. By Type - Global Neoantigen Cancer Vaccine Revenue Market Share, 2017-2028
Figure 9. By Application - Global Neoantigen Cancer Vaccine Revenue Market Share, 2017-2028
Figure 10. By Region - Global Neoantigen Cancer Vaccine Revenue Market Share, 2017-2028
Figure 11. By Country - North America Neoantigen Cancer Vaccine Revenue Market Share, 2017-2028
Figure 12. US Neoantigen Cancer Vaccine Revenue, (US$, Mn), 2017-2028
Figure 13. Canada Neoantigen Cancer Vaccine Revenue, (US$, Mn), 2017-2028
Figure 14. Mexico Neoantigen Cancer Vaccine Revenue, (US$, Mn), 2017-2028
Figure 15. By Country - Europe Neoantigen Cancer Vaccine Revenue Market Share, 2017-2028
Figure 16. Germany Neoantigen Cancer Vaccine Revenue, (US$, Mn), 2017-2028
Figure 17. France Neoantigen Cancer Vaccine Revenue, (US$, Mn), 2017-2028
Figure 18. U.K. Neoantigen Cancer Vaccine Revenue, (US$, Mn), 2017-2028
Figure 19. Italy Neoantigen Cancer Vaccine Revenue, (US$, Mn), 2017-2028
Figure 20. Russia Neoantigen Cancer Vaccine Revenue, (US$, Mn), 2017-2028
Figure 21. Nordic Countries Neoantigen Cancer Vaccine Revenue, (US$, Mn), 2017-2028
Figure 22. Benelux Neoantigen Cancer Vaccine Revenue, (US$, Mn), 2017-2028
Figure 23. By Region - Asia Neoantigen Cancer Vaccine Revenue Market Share, 2017-2028
Figure 24. China Neoantigen Cancer Vaccine Revenue, (US$, Mn), 2017-2028
Figure 25. Japan Neoantigen Cancer Vaccine Revenue, (US$, Mn), 2017-2028
Figure 26. South Korea Neoantigen Cancer Vaccine Revenue, (US$, Mn), 2017-2028
Figure 27. Southeast Asia Neoantigen Cancer Vaccine Revenue, (US$, Mn), 2017-2028
Figure 28. India Neoantigen Cancer Vaccine Revenue, (US$, Mn), 2017-2028
Figure 29. By Country - South America Neoantigen Cancer Vaccine Revenue Market Share, 2017-2028
Figure 30. Brazil Neoantigen Cancer Vaccine Revenue, (US$, Mn), 2017-2028
Figure 31. Argentina Neoantigen Cancer Vaccine Revenue, (US$, Mn), 2017-2028
Figure 32. By Country - Middle East & Africa Neoantigen Cancer Vaccine Revenue Market Share, 2017-2028
Figure 33. Turkey Neoantigen Cancer Vaccine Revenue, (US$, Mn), 2017-2028
Figure 34. Israel Neoantigen Cancer Vaccine Revenue, (US$, Mn), 2017-2028
Figure 35. Saudi Arabia Neoantigen Cancer Vaccine Revenue, (US$, Mn), 2017-2028
Figure 36. UAE Neoantigen Cancer Vaccine Revenue, (US$, Mn), 2017-2028
Figure 37. Roche Neoantigen Cancer Vaccine Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 38. Medimmune Neoantigen Cancer Vaccine Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 39. Merck Neoantigen Cancer Vaccine Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 40. Advaxis Neoantigen Cancer Vaccine Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 41. Agenus Neoantigen Cancer Vaccine Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 42. Genocea Neoantigen Cancer Vaccine Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 43. Gritstone Oncology Neoantigen Cancer Vaccine Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 44. Neon Therapeutics Neoantigen Cancer Vaccine Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 45. Nouscom Neoantigen Cancer Vaccine Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 46. OSE Immunotherapeutics Neoantigen Cancer Vaccine Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 47. Medigene Neoantigen Cancer Vaccine Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 48. Vaccibody Neoantigen Cancer Vaccine Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 49. Brightpath Biotherapeutics Neoantigen Cancer Vaccine Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 50. Geneos Therapeutics Neoantigen Cancer Vaccine Revenue Year Over Year Growth (US$, Mn) & (2017-2022)